An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6

被引：3

作者：

Bonnet-Brilhault, Frederique ^{[1
]}

Broly, Frank

Blanc, Romuald

Furet, Yves

Barthelemy, Catherine

Paintaud, Gilles

机构：

[1] INSERM, U619, F-37000 Tours, France

[2] Univ Tours, IFR 135, F-37000 Tours, France

[3] CHRU, Serv Pharmacol, F-37000 Tours, France

[4] CHU Lille, Serv Biochim & Biol Mol, F-59037 Lille, France

来源：

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 2006年 / 26卷 / 04期

关键词：

D O I：

10.1097/01.jcp.0000227352.52288.50

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：442 / 444

页数：3

共 15 条

[1] The screen for child anxiety related emotional disorders (SCARED): Scale construction and psychometric characteristics [J].

Birmaher, B ;

Khetarpal, S ;

Brent, D ;

Cully, M ;

Balach, L ;

Kaufman, J ;

Neer, SM .

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (04) :545-553

[2] Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].

Chida, M ;

Yokoi, T ;

Fukui, T ;

Kinoshita, M ;

Yokota, J ;

Kamataki, T .

JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902

[3] Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships [J].

Chou, WH ;

Yan, FX ;

Robbins-Weilert, DK ;

Ryder, TB ;

Liu, WW ;

Perbost, C ;

Fairchild, M ;

de Leon, J ;

Koch, WH ;

Wedlund, PJ .

CLINICAL CHEMISTRY, 2003, 49 (04) :542-551

[4] The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity [J].

Conners, CK ;

Sitarenios, G ;

Parker, JDA ;

Epstein, JN .

JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 1998, 26 (04) :257-268

[5]

DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419

[6] Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers [J].

DeVane, CL ;

Markowitz, JS ;

Carson, SW ;

Boulton, DW ;

Gill, HS ;

Nahas, Z ;

Risch, SC .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (03) :347-349

[7] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test [J].

Laine, K ;

Tybring, G ;

Härtter, S ;

Andersson, K ;

Svensson, JO ;

Widén, J ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :327-335

[8] RELATIONSHIP BETWEEN PERSONALITY AND DEBRISOQUINE HYDROXYLATION CAPACITY - SUGGESTION OF AN ENDOGENOUS NEUROACTIVE SUBSTRATE OR PRODUCT OF THE CYTOCHROME-P4502D6 [J].

LLERENA, A ;

EDMAN, G ;

COBALEDA, J ;

BENITEZ, J ;

SCHALLING, D ;

BERTILSSON, L .

ACTA PSYCHIATRICA SCANDINAVICA, 1993, 87 (01) :23-28

[9] Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene [J].

Lovlie, R ;

Daly, AK ;

Molven, A ;

Idle, JR ;

Steen, VM .

FEBS LETTERS, 1996, 392 (01) :30-34

[10] Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder [J].

Markowitz, JS ;

Patrick, KS .

CLINICAL PHARMACOKINETICS, 2001, 40 (10) :753-772

← 1 2 →